Eric Crampton writes – New medicines are slow to be authorised for the New Zealand market. Even if a medicine has already been approved by many other trustworthy overseas regulators like those in Canada, the UK, Australia, and the EU, Medsafe can take a very long time to evaluate a medicine.
New medicine approvals plan an exercise in not solving the problem
New medicine approvals plan an exercise in not solving the problem
28 May 2025 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, politics - New Zealand, Public Choice Tags: drug lags
Recent Comments